Legal & RegulatoryEvent: September 2, 2026
MindImmune Therapeutics reported that the FDA cleared PrecivityAD2, a blood test built on technology developed at Washington University School of Medicine, for use in patients as young as 40.
Published
Signal category
Legal & Regulatory
Quote
“The FDA just cleared PrecivityAD2, a blood test built on technology developed at Washington University School of Medicine.”
— MindImmune Therapeutics team
Company
MindImmune Therapeutics
A New Approach to Neurodegeneration
- Location
- Providence, RI, US
- Company size
- 16 employees
MindImmune is a biopharmaceutical company targeting the inflammatory drivers of Alzheimer's Disease and other neurodegenerative disorders. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in modulating the immune system to treat brain disease.